We took a close examination of NBL using cell line expression data from CCLE25 along with patient tumor data from TARGET55 for lineage factors ASCL1 and YAP1, REST targets, ISGs, MHC I, immune cell-specific signature scores48, Ayer et al.’s PD-1 blockade response signature49, immune checkpoints50, and suppressive cytokines and receptors51. This evidence concerns the gene REST and neoplasm.